-

Outset Medical to Present at Upcoming Investor Conferences

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in fireside chats at two upcoming investor conferences. Outset will participate in the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023, and the RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023.

Event: Bank of America Securities 2023 Health Care Conference
Date: Tuesday, May 9, 2023
Time: 1:40pm PT / 4:40pm ET

Event: RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 17, 2023
Time: 5:00am PT / 8:00am ET

Live and archived webcasts of the fireside chats will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.

About Outset Medical, Inc.

Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.

Contacts

Jim Mazzola
Vice President, Investor Relations
jmazzola@outsetmedical.com

Brian Johnston
Gilmartin Group
(332) 895-3222
investors@outsetmedical.com

Outset Medical, Inc.

NASDAQ:OM

Release Versions

Contacts

Jim Mazzola
Vice President, Investor Relations
jmazzola@outsetmedical.com

Brian Johnston
Gilmartin Group
(332) 895-3222
investors@outsetmedical.com

More News From Outset Medical, Inc.

Outset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of TabloCartTM with prefiltration, an innovative optional accessory for the Tablo® Hemodialysis System. Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to c...

Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced today a multi-year agreement to help accelerate home hemodialysis in the U.S. Studies show patients with end-stage kidney disease (ESKD) are healthier mentally and physically dialyzing at home, more...

Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council. This collaboration underscores Outset’s dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease. Les...
Back to Newsroom